AdvanSource Biomaterials to Formally Launch International Marketing at MedTec Ireland September 24-26
Posted on: Tuesday, 23 September 2008, 15:00 CDT
AdvanSource Biomaterials Corporation, which develops advanced polymer materials for medical device design and development, will formally launch its international marketing effort as an exhibitor at MedTec Ireland in Galway, Ireland from September 24 through September 26, 2008.
"MedTech Ireland provides the perfect venue to officially launch our newly rebranded company in the international marketplace. Many of our existing and potential customers have manufacturing facilities in Ireland, and this conference focuses on issues specific to their needs. Our mission is to inform new and existing customers about the enhancements to their medical devices that AdvanSource Biomaterials' performance polymers deliver. We are looking forward to introducing our new product extensions in this important international market. We will also be showcasing our ability to customize our proprietary polymers for specific customer applications in a wide range of device categories," noted Global Sales Director Khristine Carroll.
An application scientist from the Company will be joining Ms. Carroll at the AdvanSource Biomaterials exhibition booth # 501 to demonstrate the Company's leading edge technology, notably products such as ChronoFlex(R), HydroMed(TM), and HydroThane(TM) which have been developed to overcome a wide range of design and functional challenges, from the need for dimensional stability, ease of manufacturability and demanding physical properties to overcoming environmental stress cracking (ESC) and providing heightened lubricity for ease of insertion.
The Company will also be unveiling in Ireland its antimicrobial extension lines that complement the ChronoFlex(R) and HydroMed(TM) product families. Through proprietary manufacturing techniques, the Company has produced materials which allow for full homogenous dispersion throughout the polymer, thus resulting in long lasting and consistent activity and the prevention of leaching. The end result being a technologically advanced antimicrobial material which reduces the potential for foreign body patient infections, has a higher kill rate and is less susceptible to bacterial growth and biofilm formations.
About AdvanSource Biomaterials Corporation
AdvanSource Biomaterials develops advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource BioMaterials business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income.
AdvanSource Biomaterials' parent company, CardioTech International, Inc. (AMEX: CTE) has developed a synthetic coronary bypass graft, CardioPass(TM), currently in a clinical trial in Europe. More information about AdvanSource Biomaterials is available at its website: http://www.advbiomaterials.com.
Source: Business Wire
Related Articles
- Honeywell Helicopter Safety System is First to Receive FAA Design and Production Approval
- Yongye Biotechnology International Receives License to Manufacture Products
- FDA has Granted HUD (Humanitarian Use Device) Designation to ITGI's Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
- Zila to Market Its Proprietary Oral Cancer Screening Product, ViziLite Plus, in Russia
- Zila Adds Four Major European Markets for Its Proprietary Oral Cancer Screening Product, ViziLite Plus
- Zila to Begin Distributing Its Proprietary Oral Cancer Screening Product, ViziLite Plus, in Greece
- Generex Biotechnology Announces That It Has Produced MetControl, the Company's Proprietary Metformin Chewing Gum Product for Upcoming Clinical Study
- ALGOR Showcases V19.1 at Atlantic Design & Manufacturing 2006
- Specialized Health Products Reports First Quarter Financial Results; Company Achieves First $2 Million Revenue Quarter; Manufactured Product Sales Increase 74% to $1.4 Million
 |
 |
User Comments (0)
RSS Feeds